Feature | ESC | September 09, 2019

Highlights From the 2019 ESC Congress

Top cardiology news from the European Soceity of Cardiology 2019 meeting

ESC President Barbara Casadei, M.D., DPhil, FRCP, FESC, a British Heart Foundation Professor and an honorary consultant cardiologist at the John Radcliffe Hospital in Oxford, speaks at a press conference at the 2019 ESC Congress. #ESC19 #ESC2019

ESC President Barbara Casadei, M.D., DPhil, FRCP, FESC, a British Heart Foundation Professor and an honorary consultant cardiologist at the John Radcliffe Hospital in Oxford, speaks at a press conference at the 2019 ESC Congress.

 

September 9, 2019 — More than 33,000 health professionals gathered over five days to attend the 2019 European Society of Cardiology (ESC) congress in Paris. The event included more than 600 expert sessions covering the entire spectrum of cardiovascular medicine. There also were six Hot Line sessions showcasing 28 key clinical trials and 13 Late-breaking Science sessions, which both attracted large crowds.

“ESC Congress 2019, which was held this year with the World Congress of Cardiology, will be remembered as an exceptional vintage,”  said Professor Marco Roffi, M.D., chair of the ESC Congress Programme Committee. “Studies presented this year in the Hot Lines, such as DAPA HF, COMPLETE or ISAR REACT 5, will no doubt influence practice. To date, we have also counted 54 simultaneous publications in major medical journals.”

Congress Programme Committee Chair, Prof Silvia Priori, M.D., Ph.D., in turn highlighted other landmark studies presented, such as THEMIS and PARAGON HF, which have addressed unmet needs. “I would also like to pick out the salt substitution study from Peru that received a standing ovation and showed that with simple means physicians and communities working together can reduce cardiovascular risk.”

“We were delighted to join forces with the World Heart Federation (WHF) this year,” said ESC President Barbara Casadei, M.D., DPhil, FRCP, FESC.  “Despite all the advances in treatment that we have witnessed over the last few days, cardiovascular disease is still the number one killer in the world and there is a worrying trend in Western Europe where the rate of premature cardiovascular death has begun to increase for the first time in 50 years.”

Professor Karen Sliwa, M.D., Ph.D., FESC, FACC, WHF President commented: "Partnering with the European Society of Cardiology on this important event has been an opportunity to bring WHF's unique global perspective to the ESC Congress, contributing to making this the largest congress yet. It has been an incredible experience that has also strengthened the special partnership between WHF and ESC. A true example of joining forces in the fight against cardiovascular disease."

“Studies presented at ESC Congress get worldwide media exposure helping to promote the research presented at the event,” explained Sarah Clarke, M.D., FRCP, FESC, FACC, ESC Media Committee Chair. Not all the stories that made headlines this week came from Hot Lines. 

ESC said the top late-breaking presentations covered by the lay media included:

   • Tiny wearable cameras may improve quality of life in heart-failure patients
   • Malaria infection increases risk of heart failure
   • Eating nuts linked with lower risk of fatal heart attack and stroke
   • Lifestyle, not genetics, explains most premature heart disease
   • Twice yearly jab has the potential to reduce bad cholesterol

This year’s congress also featured the first patient forum. “We look forward to their continued involvement. Matching science with patient experience adds value,” said Casadei.

For more information: www.escardio.org

 

Other ESC 2019 News:

World Heart Federation Launches Global Roadmap on Cardiovascular Disease Prevention Among Diabetics

Superiority of Orsiro Over Xience Stent Demonstrated in STEMI Patients

Entresto Improved Measures of Heart Structure and Function in Heart Failure Patients

Global Echocardiography Normal Values Study Presented at European Society of Cardiology Congress

Complete Revascularization Superior to Culprit Lesion-only Intervention

Prasugrel Cuts Ischemic Events in Acute Coronary Syndrome Patients

Farxiga Significantly Reduces Cardiovascular Death and Worsening of Heart Failure
 

 

 

Related Content

FDA Issues Final Guidance on Live Case Presentations During IDE Clinical Trials
News | Cardiovascular Clinical Studies | July 10, 2019
The U.S. Food and Drug Administration (FDA) issued the final guidance “Live Case Presentations During Investigational...
Veradigm Partners With American College of Cardiology on Next-generation Research Registries
News | Cardiovascular Clinical Studies | July 03, 2019
The American College of Cardiology (ACC) has partnered with Veradigm, an Allscripts business unit, to power the next...
New FDA Proposed Rule Alters Informed Consent for Clinical Studies
News | Cardiovascular Clinical Studies | November 19, 2018
The U.S. Food and Drug Administration (FDA) is proposing to add an exception to informed consent requirements for...
A key slide from Elnabawi's presentation, showing cardiac CT plaque evaluations, showing the impact of psoriasis medication on coronary plaques at baseline and one year of treatment. It shows a reversal of vulnerable plaque development. #SCAI, #SCAI2018

A key slide from Elnabawi's presentation, showing cardiac CT plaque evaluations, showing the impact of psoriasis medication on coronary plaques at baseline and one year of treatment. It shows a reversal of vulnerable plaque development.  

Feature | Cardiovascular Clinical Studies | May 14, 2018
May 14, 2018 – New clinical evidance shows common therapy options for psoriasis (PSO), a chronic inflammatory skin di
Intravenous Drug Use is Causing Rise in Heart Valve Infections, Healthcare Costs. #SCAI, #SCAI2018
News | Cardiovascular Clinical Studies | May 14, 2018
May 14, 2018 — The opioid drug epidemic is impacting cardiology, with a new study finding the number of patients hosp
Patient Enrollment Completed in U.S. IDE Study of THERMOCOOL SMARTTOUCH SF Catheter
News | Cardiovascular Clinical Studies | March 15, 2018
March 15, 2018 –  Johnson & Johnson Medical Devices Companies announced today that Biosense Webster, Inc., who wo
Lexington Begins HeartSentry Clinical Trial
News | Cardiovascular Clinical Studies | February 20, 2018
February 20, 2018 – Lexington Biosciences, Inc., a development-stage medical device company, announced the commenceme
Endologix Completes Patient Enrollment in the ELEVATE IDE Clinical Study
News | Cardiovascular Clinical Studies | February 06, 2018
February 6, 2018 – Endologix, a developer and marketer of treatments for aortic disorders, announced the completion o
12-Month Results from Veryan Medical's MIMICS-2 IDE Study Presented at LINC
News | Cardiovascular Clinical Studies | February 01, 2018
February 1, 2018 – Thomas Zeller (Bad Krozingen, Germany) presented the 12-month results from Veryan Medical’s MIMICS
LimFlow Completes U.S. Feasibility Study Enrollment, Receives FDA Device Status
News | Cardiovascular Clinical Studies | February 01, 2018
February 1, 2018 –  LimFlow SA, developer of minimally-inv
Overlay Init